News
9h
GlobalData on MSNMTPA’s Radicava shows long-term benefit in ALS trials
MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...
19h
Stockhead on MSNNeurizon’s ALS drug shows safety and extended survival in open-label extension study
Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...
Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.
Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...
9h
TipRanks on MSNNeuroSense Reports Long-Term Safety of PrimeC in ALS Study
The latest update is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). As of August 20, 2025, NeuroSense Therapeutics Ltd. reported that ...
The ketamine product KETARx made by PharmaTher has been approved by the FDA for use in surgical pain management.
ProSpec-Tany TechnoGene Ltd. (prospecbio), an internationally recognized manufacturer of recombinant proteins, today highlighted the groundbreaking p ...
The Japanese launch builds on ClearStrand-ASD’s successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate ...
The onset of motor neurone disease (MND) left Sarah without a voice and the use of her hands at the age of 34. It was within ...
Texas senators approved several bills Monday, one of which included another attempt at blocking hemp-derived THC products.
22h
News-Medical.Net on MSNResearchers gain better understanding of how nerve cells can be protected against ALS
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
DelveInsight's HDAC Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results